Benjamin F. Edwards & Company Inc. cut its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 82.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,667 shares of the exchange traded fund’s stock after selling 7,680 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in SPDR S&P Biotech ETF were worth $120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of XBI. Truewealth LLC bought a new stake in SPDR S&P Biotech ETF during the 4th quarter valued at approximately $29,000. Private Ocean LLC boosted its position in SPDR S&P Biotech ETF by 73.7% during the 4th quarter. Private Ocean LLC now owns 1,761 shares of the exchange traded fund’s stock valued at $126,000 after acquiring an additional 747 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in SPDR S&P Biotech ETF by 33.0% during the 3rd quarter. Rehmann Capital Advisory Group now owns 1,435 shares of the exchange traded fund’s stock valued at $138,000 after acquiring an additional 356 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in SPDR S&P Biotech ETF during the 3rd quarter valued at approximately $153,000. Finally, Creative Financial Designs Inc. ADV boosted its position in SPDR S&P Biotech ETF by 193.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 2,277 shares of the exchange traded fund’s stock valued at $163,000 after acquiring an additional 1,500 shares in the last quarter.

SPDR S&P Biotech ETF stock opened at $83.08 on Tuesday. SPDR S&P Biotech ETF has a fifty-two week low of $64.38 and a fifty-two week high of $101.55.

ILLEGAL ACTIVITY NOTICE: “SPDR S&P Biotech ETF (XBI) Position Lessened by Benjamin F. Edwards & Company Inc.” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2019/02/12/spdr-sp-biotech-etf-xbi-position-lessened-by-benjamin-f-edwards-company-inc.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.